Serial high sensitivity troponin sampling in patients with SARS-CoV-2 infection
Copyright © 2024 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved..
INTRODUCTION: Multiple studies have investigated the role of cardiac troponin (cTn) in the risk stratification of patients with COVID-19. Most of these investigations are based on cTn values at presentation and do not consider the prognostic significance of cTn changes over time. This study aimed to investigate the prognostic role of serial cTn measurements in patients hospitalized with COVID-19 with samples that were not obtained for clinical indications.
METHODS: Patients hospitalized between April 2020 and March 2021 with PCR-confirmed SARS-CoV-2 infection were evaluated. Blood samples collected for any reason were stored for subsequent analysis. If clinical high sensitivity hs-cTnT (Roche) was not measured, samples were tested separately in batches. Hs-cTnI (Abbott) was also evaluated.
RESULTS: There were 228 unique patients. There were 21 (9.2 %) deaths. No patient with a low hs-cTnT (<6 ng/L) died and 1 patient with low hs-cTnI (<5 ng/L) died. Myocardial injury was associated with higher odds of death, when defined by hs-cTnT (OR: 7.88, 95 % CI: 2.04-30.40, p = 0.003) or hs-cTnI (OR: 7.46, 95 % CI: 2.68-20.77, p < 0.001). This association remained after propensity weighting. An increasing pattern was associated with higher odds of death compared to a stable pattern for hs-cTnT (OR: 5.45, 95 % CI: 1.81-16.40, p = 0.003) and hs-cTnI (OR: 4.49, 95 % CI: 1.02-19.81, p = 0.048). Among patients with myocardial injury defined by hs-cTnT, an increasing pattern was associated with higher odds of death compared to a decreasing pattern (OR: 4.80, 95 % CI: 1.16-19.97, p = 0.031).
CONCLUSIONS: Patients hospitalized with COVID-19 with myocardial injury have higher odds of death. Serial hs-cTn testing provides additional risk stratification in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:125 |
|---|---|
| Enthalten in: |
Clinical biochemistry - 125(2024) vom: 15. März, Seite 110732 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lobo, Ronstan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clinbiochem.2024.110732 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36855001X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36855001X | ||
| 003 | DE-627 | ||
| 005 | 20240305232407.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240217s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinbiochem.2024.110732 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM36855001X | ||
| 035 | |a (NLM)38364931 | ||
| 035 | |a (PII)S0009-9120(24)00026-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lobo, Ronstan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serial high sensitivity troponin sampling in patients with SARS-CoV-2 infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: Multiple studies have investigated the role of cardiac troponin (cTn) in the risk stratification of patients with COVID-19. Most of these investigations are based on cTn values at presentation and do not consider the prognostic significance of cTn changes over time. This study aimed to investigate the prognostic role of serial cTn measurements in patients hospitalized with COVID-19 with samples that were not obtained for clinical indications | ||
| 520 | |a METHODS: Patients hospitalized between April 2020 and March 2021 with PCR-confirmed SARS-CoV-2 infection were evaluated. Blood samples collected for any reason were stored for subsequent analysis. If clinical high sensitivity hs-cTnT (Roche) was not measured, samples were tested separately in batches. Hs-cTnI (Abbott) was also evaluated | ||
| 520 | |a RESULTS: There were 228 unique patients. There were 21 (9.2 %) deaths. No patient with a low hs-cTnT (<6 ng/L) died and 1 patient with low hs-cTnI (<5 ng/L) died. Myocardial injury was associated with higher odds of death, when defined by hs-cTnT (OR: 7.88, 95 % CI: 2.04-30.40, p = 0.003) or hs-cTnI (OR: 7.46, 95 % CI: 2.68-20.77, p < 0.001). This association remained after propensity weighting. An increasing pattern was associated with higher odds of death compared to a stable pattern for hs-cTnT (OR: 5.45, 95 % CI: 1.81-16.40, p = 0.003) and hs-cTnI (OR: 4.49, 95 % CI: 1.02-19.81, p = 0.048). Among patients with myocardial injury defined by hs-cTnT, an increasing pattern was associated with higher odds of death compared to a decreasing pattern (OR: 4.80, 95 % CI: 1.16-19.97, p = 0.031) | ||
| 520 | |a CONCLUSIONS: Patients hospitalized with COVID-19 with myocardial injury have higher odds of death. Serial hs-cTn testing provides additional risk stratification in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Troponin T |2 NLM | |
| 650 | 7 | |a Troponin I |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a De Michieli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Spears, Grant M |e verfasserin |4 aut | |
| 700 | 1 | |a Theel, Elitza S |e verfasserin |4 aut | |
| 700 | 1 | |a Donato, Leslie J |e verfasserin |4 aut | |
| 700 | 1 | |a Wockenfus, Amy M |e verfasserin |4 aut | |
| 700 | 1 | |a Kelley, Brandon R |e verfasserin |4 aut | |
| 700 | 1 | |a Jaffe, Allan S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical biochemistry |d 1970 |g 125(2024) vom: 15. März, Seite 110732 |w (DE-627)NLM000001988 |x 1873-2933 |7 nnns |
| 773 | 1 | 8 | |g volume:125 |g year:2024 |g day:15 |g month:03 |g pages:110732 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinbiochem.2024.110732 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 125 |j 2024 |b 15 |c 03 |h 110732 | ||